Thoracic Oncology
The clinical research activity at Instituto Português de Oncologia do Porto Francisco Gentil E.P.E. is centered on non-small cell lung cancer, with particular attention to early-stage and locally advanced unresectable disease. The sponsor’s trial portfolio reflects a focus on treatment pathways for patients considered for radical local therapy.
- Non-Small Cell Lung Cancer
- Early-Stage Lung Cancer
- Locally Advanced Unresectable Disease
- Radical Local Treatment
Research interest extends to disease settings where systemic and local therapies are combined in the management of thoracic malignancy.
Immuno-Oncology
The sponsor is involved in clinical research on durvalumab, an immune checkpoint inhibitor, within the context of lung cancer treatment. This places emphasis on immunotherapy strategies for patients who are candidates for definitive oncologic care.
- Durvalumab
- Immune Checkpoint Inhibition
- Immunotherapy in Lung Cancer
The therapeutic interest lies in integrating immune-based treatment with established local control approaches for thoracic malignancies.
Radiation Oncology
Clinical research also includes radiotherapy and chemoradiotherapy for patients with non-surgical lung cancer. The trial activity reflects attention to definitive radiation-based treatment in both early and locally advanced settings.
- Radiotherapy
- Chemoradiotherapy
- Definitive Local Therapy
This area of interest connects systemic immunotherapy with curative-intent thoracic radiation treatment.
